Health Robotics, a supplier of life-critical intravenous medication robots, has evolved tremendously in the last few years. The company claims that it has touched 80 percent total IV robots market share in the world, including over 90 percent of the oncology robots global market.
Recently, the company announced that its 2nd generation sterile compounding devices continued to rule the market, with 105 new contracts in 2Q2013, including 23 Robots [5 .v.STATION ONCO and 18 i.v.STATIONs] and 82 i.v.SOFT workflow software agreements with 450 total installations to this date.
Major numbers of sales were from North America, with over 75 percent of new contracts' revenue with 14 Robots and 53 i.v.SOFT agreements.
Gaspar DeViedma, Health Robotics' executive vice president and board member, said in a statement, "We are obviously extremely pleased with the best quarterly performance in the company's history and the fact that, as previously forecasted, Health Robotics has already exceeded in the first half of 2013 all of last year total sales results with 137 new contracts YTD. With over 90% 2013's revenues originating from direct sales, I'm now confident that the company has made a successful transition from its prior indirect sales channel business model, and it is no longer dependent on the sales performance of its partner companies around the world."
Health Robotics' second generation products are built to enable hospitals' to cope up with growing pressures and also to improve patient safety, increase throughput and contain cost. According to the company, its Robotics' medical devices and integrated workflow solutions help hospitals to remove life-threatening drug and diluent exchange errors, improve drug potency, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and reduce the gap between rising patient volume/acuity, scarce nursing and pharmacy staff.
DeViedma continued, “With almost 100 i.v.STATION platform 2nd Generation Robots under contract, Health Robotics has now exceeded the number of installations of its first Robot (CytoCare) and is converting customers such as Brigham & Women's Hospital and Peter McCallum Cancer Centre to its new ONCO platform. DeViedma said that the company will continue to focus on expanding its installed base and direct sales in North America.
The company even achieved new individual hospital sales within a given quarter, which is not listed in the new sales within the period.
